Pomerantz Law Firm Investigates Potential Claims Against Ionis Pharmaceuticals After Stock Plunge
Pomerantz Law Firm Investigates Potential Fraud by Ionis Pharmaceuticals
Pomerantz LLP has initiated an investigation into Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) to look into possible securities fraud connected to the company’s recent performance. This inquiry comes on the heels of Ionis's troubling announcement regarding the Phase 3 CARDIO-TTransform trial concerning their amyloid cardiomyopathy treatment, Wainua, developed with AstraZeneca. The trial did not meet its expected primary endpoint, resulting in a significant decline in Ionis's stock price on July 9, 2026, where shares plummeted by 23.9%, closing at $64.27.
The fall in stock price has raised concerns among investors about whether Ionis and its management may have engaged in deceptive practices or misrepresented material information. Those who have suffered losses are encouraged to connect with the firm to discuss potential legal action.
Pomerantz, founded over 85 years ago by Abraham L. Pomerantz—known as the
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.